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Abstract  
Introduction: Hodgkin’s disease (HD) is a common pediatric malignancy that is treated with a 
combination of chemotherapy and radiation. Although cure rates are very high (~90%), secondary 
malignancies are not uncommon and radiation has been shown to be a risk factor for their development. 
Secondary malignant neoplasms (SMNs) of the thyroid gland are common solid tumors found in patients 
treated for HD. Current literature shows that these SMNs generally appear an average of 5 -15 years 
later, even in patients under surveillance.  
Presentation of Case: We present 16 year old patient with secondary thyroid papillary carcinoma four 
years after completion of radiotherapy. 
Conclusion: This case may have implications for the future management and post radiation care of these 
patients.  
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Introduction 
Hodgkin’s disease (HD) is the most common 
malignant lymphoma found in children aged 
15-19 [1].  HD is usually treated with a 
combination of chemotherapy and low-dose 
radiation.  Radiation treatment is a well 
known risk factor in the development of 
secondary malignant neoplasms [2 ， 3]. 
These neoplasms generally appear 5-15 
years after completion of radiation treatment.  
We present a case of a 16 year old male with 
secondary thyroid papillary carcinoma, four 
years after completion of radiotherapy for 
HD manifested by a change in thyroid signal 
intensity and unilateral enlargement on CT 
without a thyroid nodule. We will also 
discuss how the unique features of this case 
may have implications for the future 
detection of SMNs and the post radiation 
care of these patients. 
Case Presentation 
A 16 year old African American male with 
no family history of cancer was diagnosed 
with stage Ib, nodular sclerosing Hodgkin’s 
disease at the age of 12 years.  At the time, 
he was found to have disease limited to the 
mediastinum.  He underwent 4 cycles of 
chemotherapy with doxorubicin, bleomycin, 
vincristine, etopside, cyclphosphamide, and 
prednisone according to COG protocol 
AHOD0031 and was also given 2100 Grey 
of localized radiation therapy to the neck 
and mediastinum. The patient did well and 
continues to remain in remission from his 
Hodgkins Disease. A routine follow-up CT 
scan 4 years later showed no evidence of 
disease. However, the right thyroid gland 
was noted to be heterogeneous and enlarged 
twice the size of the left lobe (Figure 1). 
Ultrasound of the thyroid showed a diffusely 
heterogeneous, enlarged right thyroid lobe 
with no discrete mass.  Thyroid function 
tests were within normal limits and physical 
exam revealed an easily palpable thyroid 
lobe without cervical lymphadenopathy.  
Fine needle aspiration was attempted but 
was unsuccessful due to the firm nature of 
the gland and lack of distinct mass.  
Preoperative chest x-ray revealed no 
evidence of adenopathy, lung parenchymal 
lesions or other evidence of metastatic 
disease. 
The patient was taken to the operating 
room for a thyroid lobectomy for diagnosis.  
Pathologic examination of the thyroid 
revealed a two cm papillary carcinoma with 
multiple separate microscopic nodules of 
carcinoma without evidence of 
lymphovascular or extrathyroidal extension.  
A completion thryoidectomy was then 
performed which showed no further 
evidence of papillary carcinoma giving him 
a stage 1 T1N0M0 multifocal papillary 
carcinoma of the thyroid.  Post-operatively, 
the patient received 46.3 mCi of radioactive 
iodine (I
131
).  Currently, following 
thyroidectomy and radioactive I
131
 treatment 
(2.5 and 1.5 years respectively), the patient 
is doing well with no evidence of disease.  
His thyrogen stimulated thyroglobulin level 
two years post resection is 9.2 ng/ml (within 
normal range), and his I
123
 uptake scan 
shows no uptake.    
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Figure 1 CT scan of neck.  Coronal (A, left) and axial (B, right) views of neck demonstrating an 
enlarged right thyroid lobe, prompting workup for secondary thyroid malignancy.   Arrow on both 
figures identifies enlarged right thyroid lobe. 
 
Discussion 
Malignant lymphomas in the pediatric and 
adolescent population are not a rare 
occurrence. In fact, the latest US 
Surveillance, Epidemiology, and End Results 
(SEER) data indicate that malignant 
lymphomas make up 26% of all cancers in 
the 15-19 age group [1]. Hodgkin’s Disease 
(HD), the most common subtype of the 
malignant lymphomas in this age group, is 
treated with a variable chemotherapy 
regimen (dependent upon the clinical trial of 
choice) and low dose radiotherapy to the 
affected region [2，4，5]. These pediatric 
clinical trials are pushing chemotherapy to 
the thresholds of toxicity while minimizing 
the doses of radiotherapy [5]. Although cure 
rates for HD are rising above 90% in the 
young population, secondary malignancies 
are not uncommon [6].  
The incidence of secondary malignant 
neoplasms (SMNs) following radiotherapy, 
including thyroid cancer, has been well 
documented in literature [2，3].  In three 
separate studies, the cumulative 20 year 
incidence of any SMNs was 9-17 percent[2，
3，7].  
Secondary malignant neoplasms of the 
thyroid gland are common solid tumors 
found in patients treated for HD at a young 
age [2]. Thyroid carcinoma risk is highest 
among younger patients, even when using 
radiotherapy below 20 Grey (Gy) and the risk 
of secondary thyroid cancer increases 
linearly with the dose of radiotherapy 
received [2，8-10]. There may also be a 
genetic link between HD radiotherapy and 
thyroid carcinoma. Mertens et al. report a 
nonsignificant increased risk of thyroid 
carcinoma in individuals lacking genes 
Glutathione-s-transferase M1 (GSTM1) or 
glutathione-s-transferase T1 (GSTT1) [11].  
Though the results in this study were 
nonsignificant, further studies with a larger 
A B 
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percentage of patients with thyroid 
carcinoma may yield a significant increased 
risk of development of thyroid cancer 
following HD radiotherapy. 
Development of a papillary carcinoma 
following treatment of HD was reported only 
28 months after diagnosis of HD and 22 
months after receiving 1980 cGy of 
radiotherapy in a 13.5 year old boy. This 
patient had the quickest development of a 
SMN of the thyroid reported in the literature. 
He presented with cervical lymphadenopathy, 
a globally enlarged thyroid gland, markedly 
elevated serum thyroglobulin and an 
ultrasound that revealed a large nodule. The 
diagnosis was made by fine-needle-aspiration 
[12]. According to current literature, 
development of thyroid cancer secondary to 
radiotherapy of HD is not detected until an 
average 5-15 years later, even in those 
patients under SMN surveillance (see Table 
1). 
 
Table 1 average time to development of Secondary Malignant Neoplasms of the thyroid following 
radiotherapy for Hodgkin’s disease 
References 
No. of 
patients 
in study 
Average 
age at 
radiation 
Latent period 
between irradiation 
and thyroid cancer 
diagnosis in years 
(age range) 
9]
 2 4 4 
[2] 
5 11.3 15.5 (8.2-24.4) 
[12] 
1 12 1.8 
Current Case 1 12 4 
[8] 
20 14 15.5 (5-26) 
[3] 
6 15.3 7.79-23.5  
[15] 
11 17.7 20.7 (6-38) 
[20] 
1 25 35 
[21] 
1 30 25 
 
Thyroid abnormalities can also present 
sub-clinically, as in the current case. If 
thyroid cancer is diagnosed, the standard of 
care is to remove the thyroid with a 
thyroidectomy, and to give postoperative 
radioactive iodine ablation [13]. Prophylactic 
central neck dissections to remove cervical 
lymph nodes performed at the same time as 
the thyroidectomy show no significant 
increased risk of permanent damage, 
although the benefits of central neck 
dissections are not clear [14]. 
Treatment for thyroid cancer is highly 
effective. The largest series involving 
childhood thyroid cancer patients is a 
retrospective study  from Belarus that 
reported the long term follow-up on children 
with thyroid cancer in the post Chernobyl era 
following surgical resection. Seven hundred 
and forty pediatric patients were followed for 
a mean length of 10 years and overall 
survival was 99.5% at 5 years and 98.8% at 
10 years [15-17]. Current mortality risk 
assessments show that survivors of HD 
treatment have an 18.5 year reduction in life 
expectancy, largely in part due to adulthood 
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SMNs [18]. Although the prognosis of 
papillary thyroid cancer is good, lymphatic 
seeding to the lungs is a definite risk. 
Physicians in charge for providing care to 
those with prior radiotherapy should remain 
vigilant and educate these patients on how to 
monitor changes in their thyroid structure 
and function.  
Conclusion  
The development of papillary thyroid cancer 
in our patient as well as the patient 
mentioned earlier in the discussion less than 
five years following cervical radiotherapy for 
HD is a rare occurrence that suggests that 
cancer following HD radiotherapy may be an 
earlier phenomenon than previously believed. 
This highlights that our knowledge of the 
incidence of all secondary cancers, 
specifically thyroid, prior to five years post 
HD treatment may be limited. If it is indeed 
an earlier phenomenon, it is unlikely to be 
appreciated by examination of the current 
cohort databases available given that most 
only include five year or greater patient 
survivors. In addition to the short time 
interval in the presentation of our patient’s 
carcinoma, another unique aspect is the 
atypical presentation of the SMN. Our 
patient had no identified thyroid nodule on 
physical exam or imaging, only changes in 
signal intensity and unilateral enlargement on 
routine CT. This differs from the other short 
interval case mentioned earlier in our 
discussion as that patient did in fact have a 
nodule on imaging. Our case reemphasizes 
the need to monitor the recurrence of the HD 
and also the development of possible SMNs 
at an even shorter interval after irradiation. It 
also highlights that unilateral or bilateral 
gland enlargement and signal intensity 
changes on imaging are physical exam and 
imaging characteristics that should be 
assessed for and monitored in the follow up 
post radiation care for these patients. 
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